News & Events
Stay informed about our latest scientific discoveries, pipeline progress, and corporate developments as we work to bring transformative therapies to patients.
Featured News
Basel, Switzerland
26 March 2026
FoRx Therapeutics Presents Preclinical Data at ACS Spring 2026, Confirming FORX-428's Potential for Best-in-Class PARG Inhibition
PARG is a next-generation DDR target with significant potential in PARP inhibitor-resistant cancers
Basel, Switzerland
18 December 2025
FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor
FoRx Therapeutics Announces USD 50M Series A Financing, Enabling Clinical Data Readout for Potential Best-in-Class PARG Inhibitor
Basel, Switzerland
11 August 2025
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response
FoRx Therapeutics Initiates First-in-Human Trial with Novel Anti-Cancer Drug FORX-428 Targeting DNA Damage Response.
All News
Basel, Switzerland
26 February 2025
FoRx Therapeutics AG appoints Jens Würthner as Chief Medical Officer
Basel, Switzerland
15 May 2024
Michael Kauffman appointed as Chairman of the Board of FoRx Therapeutics AG
Basel, Switzerland
3 May 2024
FoRx Therapeutics Announces Development Candidate Nomination of Potential Best-in-Class PARG Inhibitor FORX-428
Basel, Switzerland
01 August 2023
FoRx Therapeutics AG appoints Frank Zenke as Chief Scientific Officer
Basel, Switzerland
01 April 2021
FoRx Therapeutics AG appoints Tarig Bashir as Chief Executive Officer
Basel, Switzerland
01 June 2020
FoRx Therapeutics AG appoints Ulrich Lücking as Head of Chemistry
Basel, Switzerland
22 April 2020
FoRx Therapeutics AG Raises EUR 10 Million Seed Round First Company to Develop a Pipeline of Drugs Targeting DNA Replication Stress for Cancer
Media Inquiries
For press inquiries, interview requests, or media resources, please contact our communications team.
Contact Media Relations